Friday, February 10, 2012 Last update: 1:03 AM
The Best of U.S. Company Technology News
Submit Company story ideas to FreshNews.com. See our complete guidelines.
Theravance, Inc.
News articles for Theravance, Inc.:
Thursday, February 9, 2012
- Theravance Reports Fourth Quarter and Full Year 2011 Financial ResultsSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/09/12 -- Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the fourth quarter and full year ended December 31, 2011. Revenue for the full year was $24.5 million. Net loss for the fourth quarter and full year of 2011 ... read more
Wednesday, February 1, 2012
- Theravance to Present at Investor Conferences in February 2012SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/01/12 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in February 2012: Leerink Swann Global Healthcare Conference Waldorf Astoria, New York, NY Thursday, February 16, 2012 9:30 a.m. EST RBC Capital ... read more
Thursday, January 26, 2012
- Theravance to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/26/12 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2011 after market close on Thursday, February 9, 2012. An accompanying conference call will be held at 5:00 ... read more
Sunday, January 8, 2012
- GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair(TM)* in COPD and AsthmaLONDON and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/09/12 -- GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* (fluticasone furoate "FF"/vilanterol "VI") in patients with chronic obstructive pulmonary disease (COPD) and of ... read more
Friday, January 6, 2012
- Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV(R) (telavancin) for InjectionTOKYO and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/06/12 -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Theravance, Inc. (NASDAQ: THRX) today announced that Astellas has exercised its right to terminate the global License, Development and Commercialization Agreement for VIBATIV® (telavancin) for injection, a bactericidal, once-daily lipoglycopeptide antibiotic ... read more
Wednesday, December 28, 2011
- Theravance to Present at the 30th Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/28/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 9:00 a.m. PST. The conference will be ... read more
Monday, December 12, 2011
- Theravance Announces Initiation of Phase 2 Study With Its MARIN Compound, TD-9855, for the Treatment of ADHDSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/12/11 -- Theravance, Inc. (NASDAQ: THRX) announced today the initiation of an Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2 study with TD-9855, the lead compound in Theravance's MonoAmine Reuptake INhibitor (MARIN) program. TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor (NSRI) for ... read more
Monday, November 14, 2011
- Theravance Announces Positive Results From a Phase 2a Study of Its LAMA Candidate, TD-4208, for the Treatment of COPDSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/14/11 -- Theravance, Inc. (NASDAQ: THRX) announced today positive topline results from a Phase 2a single-dose study of TD-4208, an investigational inhaled long-acting muscarinic antagonist (LAMA), discovered using Theravance's multivalent approach to drug design. This compound is under development by Theravance ... read more
Tuesday, November 1, 2011
- Theravance to Present at Investor Conferences in November 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/01/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in November 2011: Credit Suisse 2011 Healthcare Conference Arizona Biltmore Hotel, Phoenix, AZ Wednesday, November 9, 2011 10:30 a.m. MST Piper Jaffray Healthcare ... read more
Wednesday, October 19, 2011
- Theravance Announces Presentation of GSK Phase 2 Data for LAMA (GSK573719) at CHEST 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/19/11 -- Theravance, Inc. (NASDAQ: THRX) today announced that data from a GlaxoSmithKline (GSK) Phase 2b study of GSK573719, a long-acting muscarinic antagonist (LAMA), in patients with chronic obstructive pulmonary disease (COPD), will be presented at CHEST 2011. The annual meeting ... read more
Thursday, October 13, 2011
- Theravance to Report Third Quarter 2011 Financial Results on October 27, 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/13/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended September 30, 2011 after market close on Thursday, October 27, 2011. An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. ... read more
Thursday, September 15, 2011
- Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSASOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/15/11 -- Astellas Pharma Europe Ltd., a subsidiary of Tokyo based Astellas Pharma Inc., and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has granted marketing authorization for VIBATIV® (telavancin hydrochloride), following the Committee for Human Medicinal Products' (CHMP) ... read more
Wednesday, August 24, 2011
- Theravance to Present at Investor Conferences in September 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/24/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Chief Executive Officer, is scheduled to present at the following investor conferences in September 2011: Stifel Nicolaus Healthcare Conference 2011 The Four Seasons Hotel, Boston, MA Wednesday, September 7, 2011 8:35 a.m. EDT Baird's ... read more
Thursday, July 28, 2011
- Theravance Reports Second Quarter 2011 Financial ResultsSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/28/11 -- Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended June 30, 2011. Revenue for the second quarter of 2011 was $6.4 million. Net loss for the second quarter of 2011 was $25.0 million or $0.31 ... read more
Thursday, July 14, 2011
- Theravance to Report Second Quarter 2011 Financial Results on July 28, 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/14/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended June 30, 2011 after market close on Thursday, July 28, 2011. An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. ... read more
Tuesday, May 24, 2011
- Theravance to Present at Investor Conferences in June 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/24/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in June 2011: Goldman Sachs 32nd Annual Global Healthcare Conference Terranea Resort, Rancho Palos Verdes, CA Tuesday, June 7, 2011 8:00 a.m. PT Rick E Winningham, ... read more
Thursday, April 28, 2011
- Theravance Reports First Quarter 2011 Financial ResultsSOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/28/11 -- Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended March 31, 2011. Revenue for the first quarter of 2011 was $6.3 million. Net loss for the first quarter of 2011 was $22.7 million or $0.28 per share. Cash, cash equivalents ... read more
Wednesday, April 20, 2011
- Theravance to Webcast 2011 Annual Meeting of Stockholders on April 27, 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/20/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2011 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Wednesday, April 27, 2011. An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight ... read more
Tuesday, April 19, 2011
- Theravance to Present at Investor Conferences in May 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/19/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in May 2011: Deutsche Bank 36th Annual Health Care Conference InterContinental Hotel, Boston, MA Tuesday, May 3, 2011 10:00 a.m. ET Rick E Winningham, Chief Executive ... read more
Thursday, April 14, 2011
- Theravance to Report First Quarter 2011 Financial Results on April 28, 2011SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/14/11 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2011 after market close on Thursday, April 28, 2011. An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. ... read more